Title: Synthesis of 213Bi-DOTATOC for peptide receptor a-therapy of GEP-NET patients refractory to β-therapy
Authors: BRUCHERTSEIFER FrankMORGENSTERN AlfredAPOSTOLIDIS ChristosGIESEL FrederikMIER WalterHABERKORN UweKRATOCHWIL Clemens
Citation: NUKLEARMEDIZIN-NUCLEAR MEDICINE vol. 52 no. 2 p. A18
Publisher: SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
Publication Year: 2013
JRC N°: JRC80486
ISSN: 0029-5566
URI: www.nuklearmedizin-online.de
http://publications.jrc.ec.europa.eu/repository/handle/JRC80486
Type: Articles in periodicals and books
Abstract: Therapy with β-emitter labelled 90Y- or 177Lu-DOTATOC is a promising option for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, some patients become refractory to treatment with beta emitters. 213Bi, an α-emitter, has demonstrated the capability to break radioresistance to β-radiation in vitro. We report a method for the synthesis of 213Bi-DOTATOC (Bi-TOC) in clinical levels and give an interim analysis of an ongoing dose escalation study assessing the toxicity and efficacy of i.a. administered Bi-TOC.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.